Search results
Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by StockNews.com to “Buy”
ETF DAILY NEWS· 4 days agoSeveral other equities research analysts have also recently commented on TEVA. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries ...
Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know - Teva Pharmaceutical Indus (NYSE:...
Benzinga· 2 days agoLoading... Loading... Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus TEVA . And retail ...
Big Pharma Teva Accused of Delaying Generic Drug Competition | Connecticut Law Tribune
Law.com· 2 days agoLawsuits against large pharmaceutical companies alleging the use of inaccurate patent listings to...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 4 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) receives a Neutral rating from JP Morgan – Knox...
Knox Daily· 4 days agoIn a filing, Teva- Pharmaceutical Industries Ltd. ADR revealed its Chief Accounting Officer Weiss Amir unloaded Company’s shares for reported $0.21 million ...
What Our Brains Know About Stocks—But Won’t Tell Us
The Wall Street Journal· 2 hours agoAmong the stocks they evaluated: AT&T Carrefour, Ralph Lauren, Sanofi and Teva Pharmaceutical For each stock, the investors viewed a basic profile,...
Amphastar maintains stock target on AMP-008 FDA approval By Investing.com
Investing.com· 1 day agoOn Thursday, Piper Sandler confirmed its Overweight rating and a $71.00 stock price target for...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 4 days agoNEW YORK, May 20, 2024 (GLOBE NEWSWIRE) -- Bleichmar Fonti & Auld LLP is investigating the WideOpenWest (NYSE: WOW) merger with DigitalBridge and Crestview. If you invested in WideOpenWest you are encouraged to obtain additional information
10 drugs now in shortage
Becker’s Hospital Review· 2 days agoAbout a month after the number of ongoing drug shortages reached a 23-year record, more than four dozen patient advocacy groups wrote to legislators, urging them to address the shortages. A ...
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
Zacks via Yahoo Finance· 3 days agoExelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic...
